1. Search Result
Search Result
Results for "

acrylamide

" in MedChemExpress (MCE) Product Catalog:

30

Inhibitors & Agonists

5

Screening Libraries

1

Fluorescent Dye

1

Biochemical Assay Reagents

10

Peptides

1

Natural
Products

6

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-29035

    Others Others
    Dopamine acrylamide, a polyphenol derivative, can cross-link collagen mainly via noncovalent bonding under acidic-non-oxidized conditions .
    Dopamine <em>acrylamide</em>
  • HY-141549

    Others Inflammation/Immunology
    BPK-21, an active acrylamide, suppresses T cell activation through blockade of ERCC3 function. BPK-21 specifically targets C342 in the helicase ERCC3 .
    BPK-21
  • HY-141550

    Others Inflammation/Immunology
    BPK-25, an active acrylamide, promotes degradation of nucleosome remodeling and deacetylation (NuRD) complex proteins by a post-translational mechanism involving covalent protein engagement. BPK-25 inhibits TMEM173 activation by the cyclic dinucleotide ligand cGAMP .
    BPK-25
  • HY-150221

    PARP Cancer
    DB008 is potent and selective PARP16 inhibitor with an IC50 value of 0.27 μM, containing an acrylamide electrophilic reagent. DB008 is membrane-permeable and marks PARP16 selectively . DB008 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    DB008
  • HY-W115727C

    acrylamide polymer,Nonionic,Mw 5-6 million

    Biochemical Assay Reagents Others
    Polyacrylamide, Nonionic, Mw 5-6 million (Acrylamide polymer, Nonionic, Mw 5-6 million) is a multifunctional polymer with moisturizing properties. Polyacrylamide,Nonionic,Mw 5-6 million is a kind of biological materials or organic compounds that are widely used in life science research .
    Polyacrylamide,Nonionic,Mw 5-6 million
  • HY-144056

    EGFR Cancer
    EGFR-IN-39 is a potent inhibitor of EGFR. EGFR-IN-39 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-39 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 2) .
    EGFR-IN-39
  • HY-144055

    EGFR Cancer
    EGFR-IN-38 is a potent inhibitor of EGFR. EGFR-IN-38 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-38 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 4) .
    EGFR-IN-38
  • HY-144054

    EGFR Cancer
    EGFR-IN-37 is a potent inhibitor of EGFR. EGFR-IN-37 is an anti-tumor agent with low toxic side effects. EGFR-IN-39 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-37 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 7) .
    EGFR-IN-37
  • HY-144052

    EGFR Cancer
    EGFR-IN-35 is a potent inhibitor of EGFR. EGFR-IN-35 is an anti-tumor agent with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-35 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 11) .
    EGFR-IN-35
  • HY-144051

    EGFR Cancer
    EGFR-IN-34 is a potent inhibitor of EGFR. EGFR-IN-34 is an anti-tumor agent with low toxic side effects. EGFR-IN-35 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-34 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 12) .
    EGFR-IN-34
  • HY-144050

    EGFR Cancer
    EGFR-IN-33 is a potent inhibitor of EGFR. EGFR-IN-33 is an anti-tumor agent with low toxic side effects. EGFR-IN-33 is an acrylamide derivative compound. Overexpression and mutation of the epidermal growth factor receptor (EGFR) has been clearly demonstrated to lead to uncontrollable cell growth and is associated with the progression of most cancer diseases, especially NSCLC. EGFR-IN-33 has the potential for the research of diseases associated with EGFR mutations (extracted from patent WO2021185348A1, compound 13) .
    EGFR-IN-33
  • HY-N2546

    Others Others
    (+)-Dehydroabietic acid is a diterpenoid. (+)-Dehydroabietic acid can be used for the acrylamide Hydrogel synthesis .
    (+)-Dehydroabietic acid
  • HY-119329

    Oxiranecarboxamide; 2,3-Epoxypropanamide

    Others Others
    Glycidamide is the genotoxic metabolite of Acrylamide. Glycidamide can react with proteins, such as hemoglobin, or with DNA, and induces genotoxic effects .
    Glycidamide
  • HY-147232

    Fluorescent Dye Others
    N-Acryloyl-1-pyrenebutylamine is a potent fluorescent derivatization agent. N-Acryloyl-1-pyrenebutylamine combines with an alkyl-acrylamide side-chain to give fluorescence function on the polymer. .
    N-Acryloyl-1-pyrenebutylamine
  • HY-132197

    Epigenetic Reader Domain Histone Acetyltransferase Cancer
    CBP/p300-IN-12 is a potent and selective covalent histone acetyltransferases p300 (IC50 of 166 nM) and CBP inhibitor. CBP/p300-IN-12 decreases the levels of H3K27Ac of PC-3 cells (EC50 of 37 nM). CBP/p300-IN-12 forms a covalent adduct with C1450 .
    CBP/p300-IN-12
  • HY-156391A

    PROTAC Linkers Cancer
    TCO4-PEG2-Maleimide is a PROTAC linker and belongs to the PEG class. TCO4-PEG2-Maleimide contains TCO and Maleimide groups, which can undergo specific "click" reactions with tetrazine groups or thiol groups, or "mercapto-acrylamide" reactions.
    (R)-TCO4-PEG2-Maleimide
  • HY-156392

    PROTAC Linkers Cancer
    TCO4-PEG7-Maleimide is a PROTAC linker and belongs to the PEG class. TCO4-PEG7-Maleimide contains TCO and Maleimide groups, which can undergo specific "click" reactions with tetrazine groups or thiol groups, or "mercapto-acrylamide" reactions.
    TCO4-PEG7-Maleimide
  • HY-W872575A

    PROTAC Linkers Cancer
    TCO4-PEG3-Maleimide is a PROTAC linker and belongs to the PEG class. TCO4-PEG3-Maleimide contains TCO and Maleimide groups, which can undergo specific "click" reactions with tetrazine groups or thiol groups, or "mercapto-acrylamide" reactions.
    (R)-TCO4-PEG3-Maleimide
  • HY-156391

    PROTAC Linkers Cancer
    TCO4-PEG2-Maleimide is a PROTAC linker and belongs to the PEG class. TCO4-PEG2-Maleimide contains TCO and Maleimide groups, which can undergo specific "click" reactions with tetrazine groups or thiol groups, or "mercapto-acrylamide" reactions.
    TCO4-PEG2-Maleimide
  • HY-W872575

    PROTAC Linkers Cancer
    TCO4-PEG3-Maleimide is a PROTAC linker and belongs to the PEG class. TCO4-PEG3-Maleimide contains TCO and Maleimide groups, which can undergo specific "click" reactions with tetrazine groups or thiol groups, or "mercapto-acrylamide" reactions.
    TCO4-PEG3-Maleimide
  • HY-P4154

    ALM-488

    Fluorescent Dye Neurological Disease
    Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves .
    Bevonescein
  • HY-163267

    Others Others
    ZNL0325 is a covalent probe based on pyrazolopyrimidine. ZNL0325 features an acrylamide side chain at the C3 position, which is capable of forming covalent bonds with multiple kinases that possess a cysteine at the αD-1 position, including BTK, EGFR, BLK, and JAK3. ZNL0325 can be used in the research of creating structurally distinct covalent kinase inhibitors .
    ZNL0325
  • HY-138565
    K-975
    Maximum Cited Publications
    12 Publications Verification

    YAP Cancer
    K-975 is a potent, selective and orally active TEAD inhibitor, with a strong inhibitory effect against protein-protein interactions between YAP1/TAZ and TEAD. K-975 covalently binds to Cys359 located in the palmitate-binding pocket of TEAD via an acrylamide structure. K-975 exhibits antitumor activity on malignant pleural mesothelioma .
    K-975
  • HY-P1103A

    CXCR Cancer
    CTCE-9908 TFA is a potent and selective CXCR4 antagonist. CTCE-9908 TFA induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908 TFA
  • HY-P1103
    CTCE-9908
    1 Publications Verification

    CXCR Cancer
    CTCE-9908 is a potent and selective CXCR4 antagonist. CTCE-9908 induces mitotic catastrophe, cytotoxicity and inhibits migration in CXCR4-expressing ovarian cancer cells .
    CTCE-9908
  • HY-P2231A

    MEDI0382 acetate

    GCGR Metabolic Disease
    Cotadutide (MEDI0382) acetate is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide acetate exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide acetate can be used in the research of obesity and type 2 diabetes (T2D) .
    Cotadutide acetate
  • HY-P2231

    MEDI0382

    GCGR Metabolic Disease
    Cotadutide (MEDI0382) is a potent dual agonist of glucagon-like peptide-1 (GLP-1) and GCGR with EC50 values of 6.9 pM and 10.2 pM, respectively. Cotadutide exhibits ability to facilitate both weight loss and glycaemic control, and alleviate fibrosis. Cotadutide can be used in the research of obesity and type 2 diabetes (T2D) .
    Cotadutide
  • HY-D1871

    Fluorescent Dye Others
    Cy3 maleimide chloride is a dye derivative of Cyanine 3 (Cy3) (HY-D0822) containing maleimide functional groups. Cy3 is a fluorescent dye with a fluorescence spectrum typically in the green to orange wavelength range. The alkyne functional group of Cy3 maleimide chloride can undergo a "thiol-acrylamide" reaction with molecules containing sulfur-oxygen functional groups to form covalent bonds. Cy3 maleimide chloride can bind to biological molecules such as proteins and antibodies to track their location and dynamic changes in biological samples.
    Cy3 maleimide chloride
  • HY-P1321

    1229U91; GW1229

    Neuropeptide Y Receptor Neurological Disease
    GR231118, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide Y Y receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide Y Y4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide YY2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide Y Y6 receptor (pKi= 8.8) .
    GR231118
  • HY-P1321A

    1229U91 TFA; GW1229 TFA

    Neuropeptide Y Receptor Neurological Disease
    GR231118 TFA, an analogue of the C-terminus of neuropeptide Y, is a potent , competitive and relative seletive antagonist at human neuropeptide YY receptor with a pKi of 10.4. GR231118 a potent agonist at the human neuropeptide YY4 receptor (pEC50=8.6; pKi=9.6) and a weak agonist at the human and rat neuropeptide Y Y2 and Y5 receptors. GR231118 also has high affinity for the mouse neuropeptide YY6 receptor (pKi= 8.8) .
    GR231118 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: